Julian Baker’s IDEAYA Biosciences IDYA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$187M Buy
5,010,030
+1,063,515
+27% +$32.6M 0.94% 17
2026
Q1
$131M Buy
3,946,515
+327,689
+9% +$11M 0.76% 20
2025
Q4
$125M Buy
3,618,826
+343,382
+10% +$10.9M 0.73% 20
2025
Q3
$89.1M Buy
3,275,444
+1,156,716
+55% +$28M 0.64% 19
2025
Q2
$44.5M Buy
2,118,728
+1,056,605
+99% +$20.3M 0.43% 26
2025
Q1
$17.4M Hold
1,062,123
0.19% 38
2024
Q4
$27.3M Hold
1,062,123
0.29% 37
2024
Q3
$33.6M Hold
1,062,123
0.35% 32
2024
Q2
$37.3M Hold
1,062,123
0.48% 29
2024
Q1
$46.6M Hold
1,062,123
0.58% 28
2023
Q4
$37.8M Hold
1,062,123
0.43% 29
2023
Q3
$28.7M Hold
1,062,123
0.17% 29
2023
Q2
$25M Buy
1,062,123
+229,354
+28% +$4.72M 0.14% 39
2023
Q1
$11.4M Sell
832,769
-835,586
-50% -$13.9M 0.06% 49
2022
Q4
$30.3M Hold
1,668,355
0.18% 29
2022
Q3
$24.9M Buy
+1,668,355
New +$21.7M 0.16% 40
2020
Q2
Sell
-126,611
Closed -$522K 116
2020
Q1
$522K Sell
126,611
-73,389
-37% -$520K ﹤0.01% 103
2019
Q4
$1.5M Hold
200,000
0.01% 88
2019
Q3
$1.8M Hold
200,000
0.01% 87
2019
Q2
$1.99M Buy
+200,000
New +$2.18M 0.01% 86

Other funds holding IDYA

Julian Baker's IDYA Position: Q2 2026 in Review

Julian Baker increased its IDEAYA Biosciences (IDYA) stake by 27% in Q2 2026, buying an estimated $32.6M and bringing the position to 5,010,030 shares worth $187M. The position accounts for 0.94% of the portfolio, ranked #17.

Julian Baker first reported a position in IDYA in Q2 2019 and has held it in 20 quarters since. 282 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

  • Julian Baker held 5,010,030 shares of IDEAYA Biosciences worth $187M as of Q2 2026.
  • Julian Baker bought 1,063,515 IDEAYA Biosciences shares in Q2 2026, an estimated $32.6M.
  • IDEAYA Biosciences made up 0.94% of Julian Baker's portfolio in Q2 2026, its #17 holding.
  • Julian Baker first reported a position in IDEAYA Biosciences in Q2 2019 and has held it in 20 quarters since.
  • 282 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.